news
New agreement to progress cardiovascular disease research
The agreement between Cartherics, The University of Sydney and The University of Queensland will further stem cell-derived heart muscle therapy for heart failure.
List view / Grid view
Disease Research
article
The power of big data to advance genomics into clinical care
The integration of genomics into patient care will lead to more precise, personalised treatments. In this Q&A, Hylton Kalvaria, Chief Commercial Officer of Helix, explains how the Helix Research Network is creating a large-scale clinicogenomics dataset to advance research into molecular and genetic determinants of disease risk and drug response.
news
The emergence of targeted alpha therapy for glioblastoma
Targeted alpha therapy shows promising preclinical results, increasing survival rate by 36.4 percent in recurrent tumours.
article
Part two: how ChatGPT enriched animal study results
Recently there has been a flurry of announcements from AI-led biotechs around the potential of Large Language Models (LLM) in early drug discovery. In the second of a three-part series, Dr Raminderpal Singh presents an example of usage of ChatGPT, which demonstrates how accessible LLMs have become for lab scientists.
news
Werner syndrome: mechanism behind atherosclerosis elucidated
Researchers have developed a new in vitro co-culture system which enables an in-depth molecular analysis of atherosclerosis.
news
Epigenetic dysregulation mechanism in Crohn’s disease discovered
Intestinal epithelial organoids highlight a pathway implicated in CD, named major histocompatibility complex (MHC)-I.
news
New silk-based membrane for organ-on-a-chip platform
The development of a new membrane which better mimics human extracellular membranes will enable more accurate disease research.
news
New biological pathway in IBD discovered
Researchers have identified a new biological pathway driving IBD and similar conditions that could be targeted with MEK inhibitors.
news
Mitigating fibrotic barriers in pancreatic cancer
A human pancreatic cancer fibrotic barrier model illuminates how targeting the TGFβ/ROCK2/YAP signalling axis could enhance drug delivery.
news
Targeting drug resistance in HER2-positive breast cancer models
Researchers discovered that HER2-positive breast cancer drugs must target both HER2 and EGFR receptors to eradicate disease.
news
Investigating CWD transmission with human cerebral organoid models
Following direct exposure of human CNS tissues to CWD prions, a significant resistance to the propagation of infection was found.
webinar
Immunotherapy advancements: transforming cancer treatment
16 May 2024 | By Drug Target Review
In recent years, immunotherapy has emerged as a revolutionary approach in cancer treatment, harnessing the power of the immune system to combat cancer cells. This webinar will explore the latest advancements in immunotherapy research, highlighting breakthroughs, challenges, and future directions in the field. Participants will gain insights, including immune checkpoint…
news
Explaining sex differences in adipose insulin resistance
Heightened insulin resistance in obese men may elucidate the higher prevalence of type 2 diabetes among these individuals.
whitepaper
Poster: Assays for PRMT5, MLL4, METTL3/14, & NSP14
AptaFluor SAH: A Homogenous, Universal Assay for Histone, RNA, & DNA Methyltransferases. Case Study for PRMT5, MLL4, METTL3/14, & NSP14
article
Women in Stem with Stefanie Flückiger-Mangual
Stefanie Flückiger-Mangual, Chief Executive Officer, is one of TOLREMO’s scientific founders and an expert in drug resistance in cancer therapy. She is a biomedical scientist and biochemist by training (University of Fribourg and ETH Zurich, Switzerland) and holds a PhD in Molecular and Translational Biomedicine from ETH Zurich. She led…
